https://www.selleckchem.com/products/MLN8237.html
45 months and duration of response was 11.17 months. PD-L1 positivity of tumor cell was possibly associated with better PFS (2.04 vs 1.41 months, cut-off 1%) and OS (11.33 vs 6.24 months, cut-off 1%). Median OS was prolonged in patients with a median number of TILs 63.75% versus ≤63.75% (11.33 vs 7.85 months). Nivolumab demonstrated continued long-term efficacy, as seen by the stability of PFS and OS, in Japanese patients with esophageal squamous cell carcinoma. Further investigation of PD-L1 tumor expression and TILs as potential b
Like
Comment
Share
